Evidence map›Paper›PMID 37175663›Full record

ArticleInternational journal of molecular sciences2023

Effects of Probiotic

Babak Pakbin, Samaneh Allahyari, Shaghayegh Pishkhan Dibazar, Leila Zolghadr, Neda Karami Chermahini, Wolfram Manuel Brück, Thomas B Brück, Razzagh Mahmoudi

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
4.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Appraisal of postbiotics in cancer therapy.Frontiers in pharmacology · 2024
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Babak PakbinInstitute for Life Technologies, University of Applied Sciences Western Switzerland Valais-Wallis, 1950 Sion, Switzerland.ORCID 0000-0003-1412-0890
Samaneh AllahyariWerner-Siemens Chair of Synthetic Biotechnology, Department of Chemistry, Technical University of Munich (TUM), Lichtenberg Str. 4, 85748 Garching bei München, Germany.
Shaghayegh Pishkhan DibazarDepartment of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran 14119-44961, Iran.ORCID 0000-0002-4811-5312
Leila ZolghadrDepartment of Chemistry, Imam Khomeini International University, Qazvin 34149-16818, Iran.
Neda Karami ChermahiniDepartment of Medicine Biotechnology, Faculty of Allied Medicine, Qazvin University of Medical Science, Qazvin 34197-59811, Iran.
Wolfram Manuel BrückInstitute for Life Technologies, University of Applied Sciences Western Switzerland Valais-Wallis, 1950 Sion, Switzerland.ORCID 0000-0002-4516-5146
Thomas B BrückWerner-Siemens Chair of Synthetic Biotechnology, Department of Chemistry, Technical University of Munich (TUM), Lichtenberg Str. 4, 85748 Garching bei München, Germany.ORCID 0000-0002-2113-6957
Razzagh MahmoudiMedical Microbiology Research Center, Qazvin University of Medical Sciences, Qazvin 34197-59811, Iran.
Siemens (Germany) · DEQazvin University of Medical Sciences · IRImam Khomeini International University · IRTarbiat Modares University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGastric cancer has been recognized as the second most probable cause of death in humans from cancer diseases around the world. Postbiotics, supernatant, and metabolites from probiotic microorganisms have recently been used widely to prevent and treat cancer diseases in humans, without any undesirable side effects. This study explores the antiproliferative and antitumor activities of the probiotic

methodsWe evaluated cell growth inhibitory and mechanical properties of the cytoplasmic membrane and the downregulation of

resultsSBS significantly inhibits the AGS cell growth, and the concentrations with IC

conclusionsConsidering the antitumor activities of SBS on AGS cell line, it can be regarded as a prospective therapeutic and preventive strategy against human stomach cancer disease.

Indexed as

ProbioticsSaccharomyces boulardiiStomach NeoplasmsCell Line, TumorCell MembraneGene ExpressionHumansSaccharomyces cerevisiaeSurvivinSurvivinAGS cell lineanticancer propertiespostbioticSaccharomyces boulardii

Identifiers

PMID37175663
PMCPMC10178855
OpenAlexW4367317433

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.